Psoriasis News & Research
Psoriasis research has produced more new treatments in the last five years than in the previous three decades combined. From targeted biologics to new topical therapies, the science is changing what clear skin means for millions of people. Here’s where things stand.
In This Guide
Latest News & Updates
The Psoriasis Research Landscape
Psoriasis research now targets specific immune pathways. The goal is to avoid suppressing the whole immune system. Scientists target interleukin-17, interleukin-23, and TYK2 pathways. Newer agents clear more skin and keep patients in remission longer than older therapies. Several next-generation treatments entered late-stage trials in 2025.
Ten years ago, most people with moderate-to-severe psoriasis started with methotrexate, cyclosporine, or light therapy. Biologics came after. Today, the treatment path looks different. Targeted biologics and oral small molecules can now clear the skin fully or nearly fully for a growing share of patients. Researchers want to extend those results to people who haven’t responded to current options.
Research is also trying to understand why psoriasis acts differently from person to person. Genetic profiling, biomarker testing, and real-world data are shifting care. The aim is to match treatments to each person rather than following a set order.
What Clinical Trials Are Testing Right Now
Active trials test next-generation IL-17 and IL-23 inhibitors, oral TYK2 blockers, and topical aryl hydrocarbon receptor agonists. Sonelokimab targets both IL-17A and IL-17F. This nanobody reported strong Phase III data in 2025. Trials are recruiting people across disease severities.
Sonelokimab is notable for its small size. As a nanobody (much smaller than a standard antibody), it blocks both IL-17A and IL-17F at once. Phase III results from 2025 showed PASI 90 responses above 75% at 52 weeks. This makes it one of the most effective agents tested so far. Deucravacitinib (Sotyktu), the first oral TYK2 inhibitor, is now being studied in new patient groups and drug combinations.
Finding a trial that fits starts with a talk with your dermatologist. ClinicalTrials.gov and the National Psoriasis Foundation’s trial finder list studies by location and severity.
Learn more: New and Emerging Psoriasis Treatments
Get Weekly Psoriasis Updates
Treatment breakthroughs, skin care strategies, and community stories.
Recent Drug Approvals
The FDA has approved several psoriasis treatments since 2022. These reflect a shift toward precision targeting. Bimzelx (bimekizumab), approved in October 2023, blocks both IL-17A and IL-17F. It cleared skin faster than several older biologics in head-to-head trials. Sotyktu (deucravacitinib), approved in 2022, was the first oral TYK2 inhibitor for plaque psoriasis. It gives people who prefer pills a new option.
On the topical side, Vtama (tapinarof) was approved in 2022. It was the first topical aryl hydrocarbon receptor agonist for plaque psoriasis. It works differently than corticosteroids. Some people stayed clear for months after stopping the cream. Researchers call this a “remittive effect.”
Each approval gives dermatologists more tools to match treatment to the person. For people who haven’t found their best option yet, having more choices matters.
Learn more: New and Emerging Psoriasis Treatments
What’s Next in the Biologics Pipeline?
The biologics pipeline includes next-generation IL-23 inhibitors that need fewer doses. It also includes dual-target nanobodies like sonelokimab and biologics paired with oral agents. Researchers are testing whether newer biologics can produce drug-free remission for months after stopping treatment.
Several pipeline candidates aim to reduce how often people need injections. Some experimental IL-23 inhibitors are tested at dosing every six months or longer. Older biologics need doses every two to four weeks. For people managing psoriasis over decades, fewer shots mean less treatment burden.
Combination research is also gaining ground. Early trials pair biologics with oral TYK2 inhibitors or topicals like tapinarof. The goal is to see if hitting multiple immune pathways at once works better than one therapy alone. These studies are still early. But they point to a trend of layered treatment plans.
Learn more: Biologics for Psoriasis: What to Know
Personalized Medicine and Psoriasis
Personalized medicine uses genetic testing, blood biomarkers, and clinical data to predict which psoriasis treatment fits you best. Researchers found gene patterns that predict response to IL-17 versus IL-23 inhibitors. But these tests are still years from routine use.
Right now, most treatment choices rely on trial and error. A dermatologist prescribes a biologic, waits 12 to 16 weeks, and checks the response. If it doesn’t work well enough, the process starts over with a new drug. Personalized medicine aims to skip that cycle by predicting the right match from the start.
Skin biopsy studies show that some people respond better to IL-17 blockade. Others do better with IL-23 inhibitors. Blood-based biomarker panels are also being built. These tools aren’t ready for routine use. But some academic centers already use them in research settings to guide treatment choices.
Learn more: New and Emerging Psoriasis Treatments
How to Join a Psoriasis Clinical Trial
You can find trials on ClinicalTrials.gov, the National Psoriasis Foundation’s trial navigator, or by asking your dermatologist. Joining is free. Most trials provide the study drug at no cost along with regular monitoring.
Each trial has rules based on psoriasis type, severity (body surface area or PASI score), past treatments, and other health conditions. Some trials seek people who haven’t responded to biologics. Others want people who are treatment-naive.
A trial means regular clinic visits, skin checks, blood draws, and sometimes photos over months or years. In return, you get access to new treatments before they reach the public. You also get close medical monitoring and help advance research.
Learn more: New and Emerging Psoriasis Treatments
Frequently Asked Questions
- What is the most recent psoriasis drug approval?
- Bimekizumab (Bimzelx), approved by the FDA in October 2023, is among the most recently approved psoriasis biologics. It blocks both IL-17A and IL-17F and showed faster and more complete skin clearance than several established biologics in head-to-head trials. Deucravacitinib (Sotyktu), the first oral TYK2 inhibitor for psoriasis, was approved in 2022.
- How do I find a psoriasis clinical trial near me?
- ClinicalTrials.gov lets you search for actively recruiting psoriasis trials by location, condition severity, and treatment history. The National Psoriasis Foundation also maintains a trial navigator tool. Your dermatologist can also point you toward studies at nearby academic medical centers.
- What does PASI score mean in psoriasis research?
- PASI stands for Psoriasis Area and Severity Index. It measures the extent and severity of plaques on a scale from 0 to 72. PASI 75 means a 75% reduction in that score from baseline, which is the standard threshold for defining treatment response in clinical trials. PASI 90 and PASI 100 represent near-complete and complete clearance, respectively.
- Are there psoriasis trials for people who have already tried biologics?
- Yes. Many trials specifically recruit people whose psoriasis did not respond adequately to one or more biologic therapies. These studies evaluate next-generation agents designed to work through different or complementary immune pathways. Your dermatologist can help determine which trials match your treatment history.
- What is the difference between a biologic and a biosimilar?
- A biologic is a complex medication derived from living cells; a biosimilar is a highly similar version of an approved biologic made by a different manufacturer after the original’s patent expires. The FDA requires biosimilars to have no clinically meaningful differences from the original. Biosimilars are helping lower costs for older psoriasis biologics like adalimumab.
- Will personalized medicine change how psoriasis is treated?
- Researchers expect it will, though routine clinical use is still years away. Gene expression studies can already identify some patients who respond better to IL-17 versus IL-23 inhibitors. As biomarker testing matures, dermatologists may be able to match patients to their best medication on the first try rather than through trial and error.
What Should You Do Next?
The fastest way to stay current on psoriasis science is to bookmark this hub and check our news section often. For a clear overview of where treatments stand today, start with New and Emerging Psoriasis Treatments. Thinking about a clinical trial? Biologics for Psoriasis: How They Work, What to Expect gives you the background to evaluate what trials test. For treatments already available, Psoriasis Treatments and Medications: A Complete Guide is the best place to start.
Research moves fast, and so do talks in our community. Join the discussion in our community forums. Or share what’s worked (or hasn’t) at Share Your Story.
Explore Our Guides
- Understanding PsoriasisLearn about the types, triggers, and diagnosis of psoriasis
- Living with PsoriasisResources for managing daily life with psoriasis
- Caregiving & SupportSelf-care, planning, and resources for care partners
- Psoriatic ArthritisUnderstanding psoriatic arthritis: symptoms, diagnosis, and treatment
- Psoriasis TreatmentsCurrent treatments, biologics, and emerging therapies
- Patient StoriesReal experiences from people living with psoriasis
Sources
- National Psoriasis Foundation. “Research Milestones.” psoriasis.org. 2024. https://www.psoriasis.org/research/
- U.S. Food and Drug Administration. “Dermatology Approvals and Safety Notifications.” fda.gov. 2024. https://www.fda.gov/drugs/resources-information-approved-drugs
- Reich K, et al. “Bimekizumab versus secukinumab in plaque psoriasis.” New England Journal of Medicine. 2021. https://doi.org/10.1056/NEJMoa2102383
- Armstrong AW, et al. “Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: POETYK PSO-2 trial.” Journal of the American Academy of Dermatology. 2023. https://doi.org/10.1016/j.jaad.2022.08.061
- Papp KA, et al. “Tapinarof in plaque psoriasis: a randomized, double-blind, phase 3 trial.” New England Journal of Medicine. 2021. https://doi.org/10.1056/NEJMoa2105762
- ClinicalTrials.gov. “Psoriasis — Recruiting Studies.” clinicaltrials.gov. 2025. https://clinicaltrials.gov/search?cond=psoriasis&recrs=a
- Hawkes JE, Chan TC, Krueger JG. “Psoriasis pathogenesis and the development of novel targeted immune therapies.” Journal of Allergy and Clinical Immunology. 2017. https://doi.org/10.1016/j.jaci.2017.07.051
- Dand N, et al. “Psoriasis drug targets and the IL-23/Th17 axis.” Journal of Investigative Dermatology. 2020. https://doi.org/10.1016/j.jid.2019.08.444